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Abstract 
Heart failure (HF) and atrial fibrillation (AF) commonly co-exist. We aimed to determine the 
prevalence and incidence of AF in ambulatory patients with HF. HF was defined by the 
presence of symptoms or signs supported by objective evidence of cardiac dysfunction: either 
a left ventricular ejection fraction (LVEF) <45% (HFrEF), or LVEF >45% and a raised plasma 
concentration of amino-terminal pro-B type natriuretic peptide (NT-proBNP>220ng/L; 
HFpEF). Of 3,570 patients with HF, 1,164 were in AF at baseline (33%), with a higher 
prevalence among patients with HFpEF compared to HFrEF (40% vs 26%, respectively, 
p<0.001). Compared to patients with HF in sinus rhythm (SR), those in AF were older, had 
more severe symptoms and higher NT-proBNP, worse renal function and were more likely to 
receive loop diuretics, despite having a higher LVEF. Of those in SR, 1,372 patients had HFrEF 
and 1,034 had HFpEF. The incidence of AF at one year (3.0%) was similar for each phenotype 
(p=0.73). Increasing age, male sex, history of paroxysmal AF and higher plasma concentrations 
of NT-proBNP  were independent predictors of incident AF during a median follow-up of 1,574 
(IQR: 749-2,821) days; the predictors were similar for each phenotype. In conclusion, the 
prevalence of AF is high, especially in patients with HFpEF, but its incidence is modest. This 
may be because their onset is near simultaneous with the development of AF precipitating the 
onset of HF. 
 
Keywords: atrial fibrillation, heart failure, prevalence, incidence, NT-proBNP. 
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Background 
Heart failure (HF) and atrial fibrillation (AF) are common, both associated with an increase in 
morbidity and mortality (1, 2), and share many of the same predisposing conditions, such as 
increasing age, hypertension, diabetes and ischaemic heart disease (3, 4).  
 
Pathophysiologically, HF and AF are closely intertwined. A constant and prolonged increase 
in atrial pressure might increase atrial wall fibrosis, impair atrial contraction, and provoke AF 
in patients with, or predisposed to, HF. In turn, the onset of AF may cause a fast ventricular 
rate, or a fall in the atrial contribution to ventricular filling, with a subsequent fall in cardiac 
output, leading to worsening of pre-existing, subclinical, ventricular dysfunction and, 
ultimately, the new-onset or clinical worsening of HF (5).  
 
The prevalence of AF in patients with heart failure and a reduced ejection fraction (HFrEF) 
enrolled in registries or clinical trials is high, ranging from 15% to 40% (6-12). It may be even 
higher (13-15) in patients with HF and preserved left ventricular ejection fraction (HFpEF), 
perhaps reflecting their older age.  However, there are few data on the incidence of new-onset 
AF in patients with HF, which may be no higher than 5%/year (4, 16).  Our aim was to 
determine the prevalence and incidence of AF in ambulatory patients with heart failure and the 
clinical predictors of new-onset AF. 
 
Methods 
 
Between 2001 and 2014, a large, epidemiologically representative cohort of patients 
with suspected heart failure has been enrolled at a single NHS community heart failure clinic 
serving a local population of about 600,000 people (The Hull LifeLab). Referrals to the heart 
failure clinic include a broad range of patients from both primary and secondary care 
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physicians. Patients are consented for the use of medical information prior to investigation. 
Some patients had no prior diagnosis of heart failure and were treatment naive, therefore 
requiring initiation of guideline-recommended treatment, or might have a pre-existing 
diagnosis of heart failure and already have been initiated on treatment that might require 
optimisation.  
Patients are reviewed by heart failure specialist nurses and doctors and are followed 
up at regular intervals, usually at 4 months, 12 months, and then yearly unless a clinical 
appointment is requested sooner by the patient, other physicians or a specialist nurse. Patients 
who develop new, or worsening symptoms, are encouraged to contact the department and are 
followed more closely if needed. Information on demography, symptoms & signs, haematology 
and biochemistry profiles (including amino-terminal pro-brain natriuretic peptide (NT-
proBNP)), and echocardiograms are systematically recorded at each time point in a dedicated 
electronic health record stored on a secure NHS server.  
Electrocardiography was systematically performed at each clinic visit to document 
heart rate and rhythm, and QRS duration. If clinically indicated, we investigated for symptoms 
of palpitations using ambulatory cardiac monitoring. Titration of treatment is coordinated by 
the clinic but often implemented by community heart failure nurses or general practitioners.  
For the purpose of the present analysis, HF was defined by the presence of symptoms 
or signs of HF supported by objective evidence of cardiac dysfunction: either a left ventricular 
ejection fraction (LVEF) <45% or equal to, or worse than mild to moderate left ventricular 
systolic dysfunction (LVSD) on visual assessment at echocardiography (HFrEF), or raised 
plasma concentration of amino-terminal pro-B type natriuretic peptide (NT-proBNP) >220 
ng/L) consistent with the European Society of Cardiology (ESC) consensus statement for 
diagnosis of HFpEF at the time of initiation of the study (17). Patients who did not fulfil criteria 
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for cardiac dysfunction (those with LVEF >45% or equal to, or better than, mild LVSD at 
visual assessment at echocardiography who had an NT-proBNP below or equal to 220 ng/l) 
were used as a control group.  
In 2016, the ESC-HF guidelines changed the definition for heart failure (18), after our 
analysis plan was developed. The new guidance suggested taking a cut-off of  LVEF<40% as 
the upper limit for making a diagnosis of HFrEF; and reduced the NT-proBNP cut-off in 
excluding heart failure to 125 ng/L. Therefore, we partially repeated our analysis applying the 
newer ESC-HF 2016 criteria, defining HF by the presence of symptoms or signs supported by 
objective evidence of cardiac dysfunction: either LVEF <40% or equal to, or worse than 
moderate LVSD on visual assessment on echocardiography (HFrEF), or raised plasma 
concentration of NT-proBNP (>125 ng/L; HFpEF, without further distinguishing between 
those with mid-range (HFmrEF) or preserved ejection fraction). 
Patients whose echocardiography, ECG or NT-proBNP (in the presence of normal or 
mildly reduced LVEF) were not available at baseline have been excluded from this analysis 
(n=511; supplementary figure 1).  
For patients in sinus rhythm at baseline, information regarding previous episodes of 
paroxysmal atrial fibrillation was retrieved from the electronic hospital records and hospital 
or General Practitioner (GP) notes before their baseline visit. We did not attempt to 
distinguish between persistent and permanent AF. 
 
Ischaemic heart disease (IHD) was defined as a previous documented history of 
myocardial infarction. Diabetes mellitus (DM) was defined as previous medical history of 
DM based on GP or hospital records or on the prescription of treatment for DM. 
Hypertension (HTN) was defined as previous medical history of HTN based on GP or 
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hospital records, or systolic blood pressure >160 mmHg or diastolic >100 mmHg at the 
baseline clinical visit, despite the use of medications that might decrease systolic or diastolic 
blood pressure (including beta-blockers, ACE-inhibitors or sartans, thiazide-like diuretics, 
and calcium-antagonists). Valvular heart disease was defined as a significant valvular 
abnormality identified as one of the causes for the referral or by baseline echocardiography, 
or a previous history of aortic or mitral valve replacement. Peripheral vascular disease (PVD) 
was defined as previous documented history of PVD, including abdominal aortic aneurysm, 
from GP or hospital records. 
Our hospital is the only hospital providing acute medical care for the region and is 
notified of all acute clinical events. It is unusual, although possible, for a patient with heart 
failure followed-up in our region to be admitted elsewhere. For patients who move out of the 
region, other clinical information, in particular death, can be tracked through hospital health 
records.  
The study conformed to the principles outlined in the Declaration of Helsinki and 
was approved by relevant ethical bodies. All participants gave their written informed consent.  
 
Categorical data are presented as numbers and percentages; normally distributed 
continuous data as mean + SD and non-normally distributed continuous variables as median 
and interquartile range. One-way ANOVA and Kruskal-Wallis tests were used to compare 
continuous variables between groups depending on the normality of the distribution, and the 
chi-squared test for categorical variables. Cox proportional hazard regression models were 
used to investigate the relationship of variables and incident AF in the overall population, and 
separately in patients with HFrEF and HFpEF. Models were constructed including and 
excluding left atrial diameter, available in <90% of patients. Treatment variables were not 
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included in either model as these might be confounded by indication and might vary over time.  
Assumptions of the models, such as multicolinearity and proportional hazards, were tested. 
Kaplan-Meier curves with the log-rank statistic were used to illustrate outcome. All analyses 
were performed using SPSS (v.22) and Stata software. A 2-sided p-value < 0.05 was 
considered statistically significant. 
 
Results 
 
Of the 5,211 patients with available data, 511 were excluded due to missing 
information (Figure 1 supplementary), leaving a total of 4,700 patients in the study. Of these, 
3,570 met the definition of heart failure and 1,130 did not (Table 1 supplementary).  
 
Of those with heart failure, 1,164 (33%) had AF on their baseline electrocardiogram. AF was 
more common in patients with HFpEF than HFrEF (40% vs 26%, respectively, p<0.001).  
Compared to patients in SR, those with AF and HF were older, had more severe symptoms, 
lower systolic blood pressure and more commonly had a clinical history of TIA/stroke and 
valvular heart disease. They also had higher plasma concentrations of NT-proBNP, worse 
renal function and were receiving more loop diuretics; on echocardiography, they had larger 
left atrial diameters, despite having a higher LVEF (Table 1).  
 
Compared to those with HFrEF and AF, those with HFpEF and AF were older and more 
likely to be women, had higher BMI and systolic blood pressure, better renal function, but 
lower haemoglobin. They also had fewer symptoms, a smaller left atrium, were less likely to 
be taking loop diuretics and had lower plasma NT-proBNP (supplementary table 2). 
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During a median follow up of 1,624 (784-3054) days, 1,962 (42%) patients with HF 
died. The presence of AF was associated with higher mortality (hazard ratio (HR) vs those in 
sinus rhythm: 1.33, 95% CI 1.20-1.47, p<0.001). Patients with HFrEF and AF had the worst 
outcome (HR: 1.19, 95% CI 1.02-1.41, p=0.026 vs those with HFpEF and AF, figure 1 
unadjusted; adjusted for age and sex, figure 2 supplementary).  
 
Compared to patients with HFrEF in SR (n = 1,372), those with HFpEF in SR (n = 1,034) 
were older, had less severe symptoms, were more likely to be women, to have hypertension 
or valvular disease, but less likely to have ischaemic heart disease (Table 1). They had lower 
NT-proBNP and haemoglobin concentrations, smaller left atria, better renal function, and 
were less frequently treated with loop diuretics. 
 
For those who had a minimum of 1 year follow-up, there was no difference in the incidence 
of persistent AF at 1 year between patients with HFrEF (n=34 of 1,195; 2.8%) and those with 
HFpEF (n=28 of 901; 3.1%; p=0.73).  
 
In univariable analysis, ischaemic heart disease, lower systolic and diastolic blood 
pressure, and higher creatinine and bilirubin were associated with incident AF (table 2). In a 
multivariable analysis that did not include left atrial diameter, only greater age, male sex, 
history of paroxysmal AF and higher NT-proBNP were independent predictors of incident 
AF. When LA diameter was entered into the model, the diagnosis of HFrEF rather than 
HFpEF and LA diameter were also independently associated with incident AF (table 2). 
 
For patients with HFrEF, increasing age, male sex, greater LogNT-proBNP and 
history of paroxysmal AF independently predicted incident AF (supplementary table 3).  
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In multivariable models for patients with HFpEF, greater Log NT-proBNP, male sex, 
and history of paroxysmal AF predicted incident AF. When LA diameter was added, it 
competed with male sex for the association with incident AF (supplementary table 4).  
Compared with the patients in the lowest quintile of NT-proBNP, those in the highest quintiles 
had 3 to 4 -fold greater risk of developing AF during follow-up (Table 3).  
 
Applying newer ESC-HF criteria, the number of patients with HF increased from 
3,570 to 3,890, of whom 1,372 had HFrEF and 2,518 had HFpEF. Compared to patients with 
HFpEF, those with HFrEF were younger (71 (63-78) vs 75 (69-81) years; p<0.001), had 
higher plasma NT-proBNP (1819 (787-4028) vs 750 (296-1757) ng/l; p<0.001) and 
creatinine (105 (88-131) vs 96 (80-122) μmol/l: p<0.001), and a larger left atrial diameter 
(4.4 (3.9-4.9) vs 4.1 (3.6-4.6) cm, p<0.001).  
 
Of 1166 patients with HF and AF at baseline (30%), the prevalence was greater amongst 
patients with HFpEF (33%) compared to HFrEF (25%; p<0.001).  
 
Of those in SR (n=2724), 2,467 had at least one-year follow-up. The incidence of persistent 
AF at one year was 2.6% and was similar in patients with HFrEF (23 of 928 patients; 2.5%) 
and HFpEF (40 of 1,539 patients; 2.6%; p=0.85). Changing the definition of heart failure did 
not change predictors of incident AF (Table 5 supplementary).  
 
Discussion 
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We previously reported the low incidence of AF in a cohort of 623 patients with 
HFrEF and sinus rhythm. Here, we expand the numbers of patients and include many more 
with HFpEF on echocardiography (19).  Our results show that in ambulatory patients with 
heart failure, the prevalence of atrial fibrillation is high, particularly in those with HFpEF, but 
its incidence is fairly low, which is most readily explained by concurrent onset of HF and AF. 
Similar observations have been made both from the Framingham study (4, 20) and Olmsted 
County residents (15). AF may often be the precipitating cause of clinically overt HF but pre-
existing ventricular dysfunction is likely to contribute both to the development AF and to a 
reduction in cardiac reserve, making the patient more vulnerable to the onset of HF.  
 
Our findings confirm the association between well-known risk factors and incident 
AF, which maintain their clinical importance regardless of left ventricular phenotype. We 
found that incident AF is more common in older individuals and men, perhaps reflecting an 
association with ischaemic heart disease. 
 
Raised plasma concentrations of natriuretic peptides are associated with an 
increasing risk of developing AF in the general population and in individuals at increased 
cardiovascular risk, but little is known about the association of natriuretic peptides with 
incident AF in ambulatory patients with HF, particularly in those with HFpEF. We found a 
linear increase in the risk of developing AF with increasing plasma concentrations of NT-
proBNP regardless of left ventricular phenotype.  
 
In almost 4,000 participants in the Cardiovascular Health Study aged older than 65 
years and free of AF, of whom only 3% had HF, those in the highest quintile of baseline NT-
proBNP had a 5.2 fold greater risk of developing AF during follow-up compared with the 
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lowest quintile (21). In a report including more than 26,000 individuals enrolled from five 
distinct community-based cohort studies conducted in the US and Europe, of whom fewer 
than 4% had HF, increasing plasma concentrations of natriuretic peptides were, along with 
increasing age, one of the strongest predictors of incident AF (22). In a Swedish cohort of 
patients free of cardiovascular disease, natriuretic peptides, particularly MR-proANP, but not 
other biomarkers (including mid-regional pro-adrenomedullin, cystatin C, and copeptin), 
predicted incident AF (23).  
 
Other authors have shown that increasing plasma concentrations of natriuretic 
peptides are robust predictors of the recurrence of AF following ablation in patients with lone 
AF (24) or of recurrence in those with a history of paroxysmal AF (25).  In a retrospective 
analysis from the Valsartan Heart Failure Trial (Val-HeFT), in which >4,000 patients had 
HFrEF and sinus rhythm, a BNP at study entry above the median value (97pg/ml) was the 
strongest predictor of AF occurrence (6.5% at 23 months) (12).  
 
Although it is possible that raised levels of natriuretic peptides might promote atrial 
arrhythmias, it is more likely that higher plasma concentrations reflect advanced age and 
more advanced underlying cardiac and renal disease. In addition, higher natriuretic peptides 
are associated with atrial enlargement and dysfunction, often secondary to left ventricular 
dysfunction (26). We found a similar incidence of AF regardless of LVEF, similar to other 
reports (27). Our results also confirm that patients with heart failure and atrial fibrillation 
have a poorer outcome compared to those in sinus rhythm, regardless of LVEF (28). 
 
We defined “incident AF” as documented AF on a 12-lead ECG at a follow up visit. 
We did not systematically investigate patients for paroxysmal AF using cardiac monitoring 
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because the clinical or therapeutic relevance of short, asymptomatic episodes of AF in 
patients with heart failure is not known and guidelines on heart failure do not recommend 
routine investigation (29). Some incident AF might have occurred shortly before death and 
would thus not have been reported. Other potential confounders, such time-dependent 
changes in medications or compliance to heart failure medications have not been 
assessed. Some patients were treatment-naïve at the time of referral or required adjustment in 
heart failure medications, which might have affected the risk of developing atrial fibrillation 
during their first year of follow-up. We included patients with either reduced LVEF below 
45% or raised natriuretic peptides (NT-proBNP >220 ng/l) in this analysis, in agreement with 
ESC recommendation that were contemporary when the study was conceived. However, 
there is no universal agreement on the optimal cut-off of NT-proBNP to be used to diagnose, 
or to rule out, HF in the presence of a normal, or mildly reduced LVEF.  The use of a lower 
cut-off to rule out HF (125ng/L), as suggested by the recent ESC-HF guidelines (18), led to 
the inclusion of patients with less severe cardiac dysfunction and a lower prevalence of AF 
amongst patients with HFpEF, reflecting the uncertainty about the diagnostic criteria for heart 
failure. However, predictors and the one-year incidence of AF remained similar for both 
HFrEF and HFpEF.  
 
In conclusions, the prevalence of AF is high, especially in patients with HFpEF but 
its incidence is modest. This may be explained by a high concurrent onset of HF and AF. 
Greater age, a prior history of paroxysmal AF and increasing plasma concentrations of NT-
proBNP, a marker of congestion, predict the risk of developing, or progressing to, persistent or 
permanent AF in patients with HF. 
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Legend to figures 
 
Figure 1: Kaplan Meier curve for death from all causes. Patients with HFrEF and AF had the 
worst outcome (HR: 1.19, 95% CI 1.02-1.41, p=0.026 vs those with HFpEF and AF). 
 
Figure 1 supplementary: Consort diagram showing the number of patients with suspected 
heart failure referred to our clinic between 2001 and 2014. 
 
Figure 2 supplementary: Kaplan Meier curve for death from all causes, adjusted for age and 
sex. Patients with HFrEF and AF had the worst outcome (HR: 1.29, 95% CI 1.09-1.52, 
p=0.003 vs those with HFpEF and AF; adjusted for age and sex). 
 
 



Variable Missing  Heart Failure and 
Atrial Fibrillation 
(1164) 
Heart Failure and 
Sinus Rhythm 
(2406) 
p HFrEF in Sinus 
Rhythm 
 (1372) 
HFpEF in Sinus 
Rhythm  
(1034) 
p 
Demographics 
Age  (Years) 0 76 (70-82) 73 (65-79) <0.001 71 (63-77) 76 (70-82) <0.001 
Men  0 774 (67%) 1483 (62%) 0.005 1002 (73%) 481 (47%) <0.001 
Body Mass Index (kg/m2) 11 28 (25-32) 28 (25-32) 0.07 28 (24-31) 28 (25-32) <0.001 
Systolic Blood Pressure  (mmHg) 11 136 (25) 139 (26) <0.001 132 (24) 149 (26) <0.001 
Diastolic Blood Pressure (mmHg) 10 80 (16) 77 (14) <0.001 76 (13) 78 (14) <0.001 
Heart Rate (bpm) 10 81 (20) 71 (15) <0.001 72 (15) 70 (15) <0.001 
Diabetes Mellitus 0 278 (24%) 603 (25%) 0.444 326 (24%) 277 (27%) 0.090 
Hypertension  0 629 (54%) 1238 (52%) 0.147 563 (41%) 675 (65%) <0.001 
Valvular Disease 0 192 (17%) 181 (8%) <0.001 75 (6%) 106 (10%) <0.001 
Ischemic Heart Disease  0 483 (42%) 1425 (59%) <0.001 956 (70%) 469 (45%) <0.001 
Previous TIA/Stroke 0 144 (12%) 163 (7%) <0.001 103 (8%) 60 (6%) 0.100 
Peripheral Vascular Disease 0 76 (7%) 179 (7%) 0.322 113 (8%) 66 (6%) 0.086 
Paroxysmal Atrial Fibrillation  0 Not applicable 190 (8%) Not applicable 116 (9%) 74 (7%) 0.242 
NYHA Class I  
0 
174 (15%) 583 (24%) 
<0.001 
268 (20%) 315 (31%) 
<0.001 
NYHA Class II  571 (49%) 1156 (48%) 682 (50%) 474 (46%) 
NYHA Class III  399 (34%) 618 (26%) 386 (28%) 232 (22%) 
NYHA Class IV  20 (2%) 49 (2%) 36 (2%) 13 (1%) 
Blood results 
NT-proBNP (ng/L) 11 1936 (1057-3607) 833 (372-2119) <0.001 1165 (474-3012) 587 (326-1288) <0.001 
Albumin (g/L) 233 37 (4) 38 (4) 0.001 38 (4) 37 (4) 0.002 
Bilirubin (µmol/L) 243 16 (13-21) 13 (11-17) <0.001 14 (12-18) 13 (10-15) <0.001 
Creatinine (µmol/L) 153 104 (86-130) 100 (82-128) 0.002 102 (86-128) 96 (79-125) <0.001 
Haemoglobin (g/dL) 157 13.4 (1.9) 13.1 (1.7) <0.001 13.4 (1.7) 12.8 (1.7) <0.001 
K (mmol/L) 171 4.3 (4.0-4.6) 4.4 (4.1-4.7) <0.001 4.4 (4.1-4.7) 4.3 (4.1-4.7) 0.001 
Na (mmol/L) 151 138 (3) 138 (3) 0.894 138 (3) 138 (3) 0.584 
Urea (mmol/L) 151 7.1 (5.4-9.8) 6.8 (5.2-9.2) 0.003 6.8 (5.3-9.2) 6.8 (5.2-9.2) 0.640 
Thyroid-Stimulating Hormone (mU/L) 408 1.8 (1.2-2.8) 1.7 (1.1-2.5) 0.002 1.6 (1.0-2.5) 1.7 (1.1-2.6) 0.151 
Medications# 
Loop diuretic 0 860 (74%) 1505 (63%) <0.001 959 (70%) 546 (53%) <0.001 
Mineralocorticoid receptor antagonist 0 227 (20%) 525 (22%) 0.111 417 (30%) 108 (10%) <0.001 
ACE-I or ARB 0 812 (70%) 1743 (72%) 0.096 1115 (81%) 628 (61%) <0.001 
Beta-blockers 0 660 (57%) 1429 (59%) 0.126 906 (66%) 523 (51%) <0.001 
Echocardiography* 
Left Ventricular Ejection Fraction >55%  
0 
403 (35%) 618 (26%) 
<0.001 
 
0 618 (60%) 
Not applicable 
Left Ventricular Ejection Fraction: 46-54% 283 (24%) 416 (17%) 0 416 (40%) 
Left Ventricular Ejection Fraction: 36-45%  242 (21%) 658 (27%) 658 (48%) 0 
Left Ventricular Ejection Fraction: <35%  236 (20%) 714 (30%) 714 (52%) 0 
Left Atrial Diameter (cm) 431 4.7 (0.8) 4.0 (0.7) <0.001 4.2 (1.7) 3.9 (0.7) <0.001 
Events 
Incident Atrial Fibrillation 0 Not applicable 291 (12%) Not applicable 205 (15%) 86 (8%) Not applicable 
Incident Atrial Fibrillation at 1 year  0 Not applicable 62 (3%) Not applicable 34 (3%) 28 (3%) 0.73 
 
Table 1: Baseline characteristics of patients with HF, by diagnostic category and by heart rhythm. *Left Ventricular Ejection Fraction was measured (n=2013) 
or visually estimated. # Medications recorded at baseline prior to changes subsequent to initial referral. 
 
Variable Univariable analysis 
 
Multivariable analysis 
LA included 
LA excluded 
 
HR (95% CI) 2 p-value HR (95% CI) 2 p-value 
Age (1 Year increase) 1.03 (1.01-1.05) 17.69 <0.001 1.04 (1.02-1.05) 
1.03 (1.02-1.05) 
17.75 
16.90 
<0.001 
<0.001 
Male sex (vs female)  1.70 (1.31-2.21) 15.59 <0.001 1.64 (1.17-2.30) 
1.98 (1.45-2.70) 
8.29 
18.75 
0.004 
<0.001 
Body Mass Index (kg/m2) 0.99 (0.98-1.02) 0.014 0.91    
Systolic Blood Pressure (mmHg) 0.99 (0.99-1.00) 6.34 0.012    
Diastolic Blood Pressure (mmHg) 0.99 (0.98-1.00) 6.23 0.013    
Heart Rate (bpm) 1.00 (1.00-1.01) 0.19 0.66    
Diabetes Mellitus  (yes vs not) 1.12 (0.85-1.48) 0.68 0.41    
Hypertension (yes vs not) 0.89 (0.71-1.12) 0.99 0.32    
Valvular Disease (yes vs not) 1.13 (0.73-1.76) 0.29 0.59    
Ischemic Heart Disease (yes vs not) 1.40 (1.10-1.80) 7.16 0.007    
Previous TIA/Stroke (yes vs not) 0.95 (0.59-1.53) 0.05 0.95    
Peripheral Vascular Disease (yes vs not) 1.11 (0.71-1.75) 0.21 0.65    
Paroxysmal Atrial Fibrillation (yes vs not) 3.06 (2.26-4.13) 53.20 <0.001 2.52 (1.78-3.57) 
2.62 (1.89-3.64) 
27.18 
33.28 
<0.001 
<0.001 
NYHA class (III/IV vs I/II) 1.40 (1.08-1.81) 6.54 0.010    
LogNT-proBNP (ng/L) 2.39 (1.94-2.96) 64.69 <0.001 1.80 (1.34-2.42) 
1.91 (1.46-2.50) 
15.19 
22.04 
<0.001 
<0.001 
Albumin (g/l) 0.97 (0.94-1.00) 3.58 0.057    
Bilirubin (µmol/L) 1.03 (1.01-1.05) 13.53 <0.001    
 
 
 
Table 2: Univariable and multivariable analysis for the incidence of atrial fibrillation in the overall population with heart failure. Two models 
were constructed, one including and one excluding left atrial diameter (available for 2085 patients, 87%). Variable included in the multivariable 
models were: age, sex, systolic blood pressure, diastolic blood pressure, ischaemic heart disease, paroxysmal atrial fibrillation, LogNT-proBNP, 
albumin, bilirubin, haemoglobin, urea, diagnostic category (HFrEF vs HFpEF) and left atrial diameter.  
Creatinine (µmol/L) 1.01 (1.00-1.01) 7.32 0.007    
Haemoglobin (g/dL) 0.94 (0.87-1.00) 3.28 0.070    
K (mmol/L) 1.03 (0.81-1.31) 0.06 0.81    
Na (mmol/L) 1.01 (0.97-1.05) 0.11 0.74    
Urea (mmol/L) 1.04 (1.02-1.06) 15.67 <0.001    
Thyroid-Stimulating Hormone  (mU/L) 1.02 (0.99-1.04) 1.83 0.18    
HFrEF vs  HFpEF 1.63 (1.27-2.09) 14.33 <0.001 1.44 (1.02-2.04) 
- 
4.36 
- 
0.037 
- 
Left Atrial Diameter (cm) 1.78 (1.50-2.12) 42.86 <0.001 1.56 (1.28-1.89) 
- 
20.17 
- 
<0.001 
- 
 
 
Quintile of NT-proBNP (range, ng/L) Patients with HFrEF with incident AF 
(per 1000 person-years), n 
Hazard ratio (95% CI), p (vs Q1) 
Q1 (9-363) 14.44 1 
Q2 (364-832) 25.51 1.80 (1.12-2.92); 0.016 
Q3 (835-1652) 39.85 2.89 (1.82-4.58);<0.001 
Q4 (1667-3780) 41.94 3.11 (1.93-4.99); <0.001 
Q5 (3781-61888) 42.53 3.18 (1.93-5.25); <0.001 
Quintile of NT-proBNP (range, ng/L) Patients with HFpEF with incident AF 
(per 1000 person-years), n 
Hazard ratio (95% CI), p (vs Q1) 
Q1 (221-309) 8.95 1 
Q2 (310-448) 9.22 1.03 (0.44-2.42); 0.948 
Q3 (449-762) 15.28 1.64 (0.74-3.62); 0.223 
Q4 (763-1573) 30.71 3.26 (1.59-6.69);0.001 
Q5 (1575-35000) 41.57 4.29 (2.12-8.70);<0.001 
 
Table 3. Risk of developing AF during follow-up according to NTproBNP quintiles in patients with HFrEF and HFpEF. 
 
Variable Missing 
values 
No evidence of heart failure 
(n=1130) 
Heart Failure 
 (n=3570) 
p 
Demographics 
Age (Years) 0 68 (59-75) 74 (66-80) <0.001 
Men  0 582 (52%) 2257 (63%) <0.001 
Body Mass Index  (kg/m2) 16 29 (26-33) 27 (24-31) <0.001 
Systolic Blood Pressure (mmHg) 28 146 (21) 138 (26) <0.001 
Diastolic Blood Pressure (mmHg) 28 83 (12) 78 (14) <0.001 
Heart Rate (bpm) 12 71 (14) 74 (18) <0.001 
Diabetes Mellitus  0 275 (24%) 881 (25%) 0.816 
Hypertension  0 667 (59%) 1867 (52%) <0.001 
Valvular Disease 0 41 (4%) 373 (10%) <0.001 
Ischemic Heart Disease 0 291 (26%) 1908 (53%) <0.001 
Previous TIA/Stroke  0 45 (4%) 307 (9%) <0.001 
Peripheral Vascular Disease 0 32 (3%) 255 (7%) <0.001 
Atrial Fibrillation 0 7 (1%) 1164 (33%) <0.001 
Paroxysmal Atrial Fibrillation  0 39 (4%) 191 (5%) 0.010 
NYHA Class I 0 581 (52%) 757 (21%) <0.001 
NYHA Class II  400 (35%) 1727 (48%) 
NYHA Class III  140 (12%) 1017 (29%) 
NYHA Class IV  9 (1%) 69 (2%) 
Blood results 
NT-proBNP (ng/L) 11 88 (48-142) 1176 (502-2696) <0.001 
Albumin (g/l) 288 39 (3) 37 (4) <0.001 
Bilirubin (µmol/L) 300 13 (11-16) 14 (12-18) <0.001 
Creatinine (µmol/L) 184 82 (71-97) 102 (83-128) <0.001 
Haemoglobin (g/dL) 239 13.9 (1.4) 13.2 (1.8) <0.001 
K (mmol/L) 213 4.3 (4.0-4.5) 4.4 (4.1-4.7) 0.301 
Na (mmol/L) 184 139 (3) 138 (3) <0.001 
Urea (mmol/L) 184 5.3 (4.3-6.5) 6.9 (5.3-9.4) <0.001 
Thyroid-Stimulating Hormone (mU/L) 592 1.6 (1.0-2.2) 1.7 (1.1-2.6) <0.001 
Medications# 
Loop diuretic  0 289 (26%) 2365 (66%) <0.001 
Mineralocorticoid receptor antagonist 0 35 (3%) 752 (21%) <0.001 
ACE-I or ARB  0 482 (43%) 2565 (72%) <0.001 
Beta-blockers  0 322 (29%) 2089 (59%) <0.001 
Echocardiography* 
Left Ventricular Ejection Fraction >55%  0  890 (79%) 1021 (29%) <0.001 
Left Ventricular Ejection Fraction: 46-54% 240 (21%) 699 (19%) 
Left Ventricular Ejection Fraction: 36-45%  0 900 (25%) 
Left Ventricular Ejection Fraction: <35%  0 950 (27%) 
Left Atrial Diameter (cm) 546 3.6 (0.6) 4.3 (0.8) <0.001 
Events  
Incident Atrial Fibrillation 0 30 (3%) 291 (12%) Not applicable 
 
Table 1 supplementary: Characteristics of patients at baseline, by diagnosis. *Left ventricular ejection fraction was measured (n=2660) or 
visually estimated. # Medications recorded at baseline prior to changes subsequent to initial referral. 
 
 
Variable HFrEF & Atrial 
Fibrillation   
(n=478) 
HFpEF & Atrial 
Fibrillation 
 (n=686) 
p 
Demographics 
Age (Years)  75 (68-81) 77 (71-82) <0.001 
Men  383 (80%) 391 (57%) <0.001 
Body Mass Index  (kg/m2) 28.0 (5.5) 29.8 (6.9) <0.001 
Systolic Blood Pressure (mmHg) 129 (24) 141 (24) <0.001 
Diastolic Blood Pressure (mmHg) 79 (16) 81 (15) 0.108 
Heart Rate (bpm) 83 (21) 80 (19) 0.009 
Diabetes Mellitus  105 (22%) 173 (25%) 0.200 
Hypertension  219 (46%) 410 (60%) <0.001 
Valvular Disease 59 (12%) 133 (19%) 0.001 
Ischemic Heart Disease 270 (57%) 213 (31%) <0.001 
Previous TIA/Stroke  70 (15%) 74 (11%) 0.049 
Peripheral Vascular Disease 34 (7%) 42 (6%) 0.501 
NYHA Class I  48 (10%) 126 (18%) 
<0.001 
NYHA Class II  223 (47%) 348 (51%) 
NYHA Class III  199 (41%) 200 (29%) 
NYHA Class IV  8 (2%) 12 (2%) 
Blood results 
NT-proBNP (ng/L) 2809 (1587-5051) 1507 (921-2651) <0.001 
Albumin (g/l) 37 (4) 38 (4) 0.067 
Bilirubin (µmol/L) 18 (14-23) 16 (13-20) <0.001 
Creatinine (µmol/L) 111 (92-136) 99 (82-125) <0.001 
Haemoglobin (g/dL) 13.6 (1.8) 13.2 (1.8) 0.001 
K (mmol/L) 4.3 (0.5) 4.3 (2.0) 0.373 
Na (mmol/L) 138 (3) 138 (3) 0.566 
Urea (mmol/L) 7.4 (5.5-10.4) 6.9 (5.3-9.4) 0.043 
Thyroid-Stimulating Hormone (mU/L) 1.8 (1.2-2.9) 1.7 (1.1-2.8) 0.402 
Medications# 
Loop diuretic 379 (79%) 481 (70%) <0.001 
 
 
 
 
 
 
 
Table 2 supplementary: Baseline characteristics of patients with HF in AF, by diagnostic category. * Left Ventricular Ejection Fraction was 
measured (n=591) or visually estimated. # Medications recorded at baseline prior to changes subsequent to initial referral. 
 
 
Mineralocorticoid receptor antagonist 127 (27%) 100 (15%) <0.001 
ACE-I or ARB 374 (78%) 438 (64%) <0.001 
Beta-blockers 285 (60%) 375 (55%) 0.093 
Echocardiography* 
Left Ventricular Ejection Fraction >55% Not applicable 403 (35%) Not applicable 
Left Ventricular Ejection Fraction: 46-54% Not applicable 283 (24%) 
Left Ventricular Ejection Fraction: 36-45%  242 (21%) Not applicable 
Left Ventricular Ejection Fraction: <35%  236 (20%) Not applicable 
Left Atrial Diameter (cm) 4.8 (4.4-5.2) 4.6 (4.2-5.1) 0.001 
Variable Univariable analysis 
 
Multivariable analysis 
LA included 
LA excluded 
 
HR (95% CI) 2 p-value HR (95% CI) 2 p-value 
Age (1 Year increase) 1.04 (1.02-1.05) 27.36 <0.001 1.04 (1.02-1.06) 
1.03 (1.02-1.05) 
14.86 
13.66 
<0.001 
<0.001 
Male sex (vs female) 1.34 (0.96-1.88) 2.87 0.09 1.70 (1.09-2.64) 
1.86 (1.25-2.78) 
5.55 
9.40 
0.018 
0.002 
Body Mass Index (kg/m2) 0.99 (0.97-1.02) 0.27 0.60    
Systolic Blood Pressure (mmHg) 0.99 (0.99-1.00) 1.06 0.30    
Diastolic Blood Pressure (mmHg) 0.99 (0.99-1.00) 2.18 0.14    
Heart Rate (bpm) 1.00 (0.99-1.01) 0.01 0.91    
Diabetes Mellitus  (yes vs not) 1.17 (0.84-1.61) 0.88 0.35    
Hypertension (yes vs not) 1.05 (0.79-1.39) 0.12 0.73    
Valvular Disease (yes vs not) 1.47 (0.85-2.53) 1.94 0.16    
Ischemic Heart Disease (yes vs not) 1.29 (0.94-1.76) 2.47 0.12    
Previous TIA/Stroke (yes vs not) 0.65 (0.34-1.23) 1.77 0.18    
Peripheral Vascular Disease (yes vs not) 0.77 (0.42-1.41) 0.73 0.39    
Paroxysmal Atrial Fibrillation (yes vs not) 3.07 (2.13-4.42) 36.26 <0.001 2.25 (1.46-3.47) 
2.30 (1.50-3.53) 
13.47 
15.52 
<0.001 
<0.001 
NYHA class (III/IV vs I/II) 1.17 (0.86-1.59) 1.00 0.32    
LogNT-proBNP (ng/L) 2.04 (1.61-2.57) 33.90 <0.001 1.64 (1.19-2.27) 9.01 0.003 
 
 
Supplementary Table 3: Univariable and multivariable analysis for the incidence of atrial fibrillation in patients with heart failure and reduced 
ejection fraction (HFrEF). Two models were constructed, including or excluding left atrial diameter. Variables included in the multivariable 
models were: age, sex, paroxysmal atrial fibrillation, Log NTproBNP, bilirubin, haemoglobin, urea, thyroid-stimulating hormone. 
 
1.66 (1.23-2.25) 10.85 0.001 
Albumin (g/l) 0.95 (0.92-0.99) 6.68 0.010    
Bilirubin (µmol/L) 1.02 (1.00-1.04) 3.85 0.05    
Creatinine (µmol/L) 1.01 (1.00-1.01) 6.39 0.011    
Haemoglobin (g/dL) 0.88 (0.81-0.96) 9.40 0.002    
K (mmol/L) 1.19 (0.89-1.58) 1.34 0.25    
Na (mmol/L) 1.02 (0.97-1.06) 0.42 0.52    
Urea (mmol/L) 1.03 (1.01-1.05) 6.93 0.008    
Thyroid-Stimulating Hormone  (mU/L) 1.02 (1.00-1.04) 4.38 0.036    
Left Atrial Diameter (cm) 1.56 (1.27-1.92) 17.45 <0.001 1.44 (1.14-1.81) 
- 
9.53 
- 
0.002 
- 
Variable Univariable analysis 
 
Multivariable analysis 
LA included 
LA excluded 
 
HR (95% CI) 2 p-value HR (95% CI) 2 p-value 
Age (1 Year increase) 1.02 (1.00-1.04) 2.59 0.11    
Male sex (vs female) 1.87 (1.21-2.89) 7.94 0.005 - 
2.08 (1.30-3.31) 
- 
9.34 
- 
0.002 
Body Mass Index (kg/m2) 1.01 (0.98-1.05) 0.37 0.54    
Systolic Blood Pressure (mmHg) 0.99 (0.98-1.00) 0.75 0.39    
Diastolic Blood Pressure (mmHg) 0.99 (0.97-1.00) 2.53 0.11    
Heart Rate (bpm) 1.00 (0.99-1.01) 0.02 0.88    
Diabetes Mellitus  (yes vs not) 0.94 (0.56-1.59) 0.05 0.83    
Hypertension (yes vs not) 0.86 (0.56-1.33) 0.44 0.51    
Valvular Disease (yes vs not) 0.91 (0.42-1.97) 0.06 0.81    
Ischemic Heart Disease (yes vs not) 1.28 (0.84-1.96) 1.33 0.25    
Previous TIA/Stroke (yes vs not) 1.78 (0.86-3.69) 2.42 0.12    
Peripheral Vascular Disease (yes vs not) 2.05 (1.03-4.11) 4.15 0.042    
Paroxysmal Atrial Fibrillation (yes vs not) 3.29 (1.94-5.60) 19.34 <0.001 2.89 (1.51-5.54) 
3.50 (2.03-6.05) 
10.32 
20.23 
0.001 
<0.001 
NYHA class (III/IV vs I/II) 1.82 (1.13-2.93) 6.09 0.014    
LogNT-proBNP (ng/L) 3.38 (2.12-5.39) 26.40 <0.001 2.60 (1.41-4.81) 
2.86 (1.69-4.83) 
9.36 
15.36 
0.002 
<0.001 
 
 
Supplementary table 4: Univariable and multivariable analysis for the incidence of atrial fibrillation in patients with heart failure and preserved 
ejection fraction (HFpEF). Two models were constructed, one including and one excluding left atrial diameter. Variable included in the 
multivariable models were: Sex, peripheral vascular disease, paroxysmal atrial fibrillation, NYHA IV/III vs I/II, Log NTproBNP, Bilirubin, K, 
Urea.  
 
 
Albumin (g/l) 1.00 (0.94-1.06) 0.01 0.94    
Bilirubin (µmol/L) 1.04 (1.02-1.07) 8.22 0.004    
Creatinine (µmol/L) 1.00 (1.00-1.01) 0.18 0.67    
Haemoglobin (g/dL) 1.03 (0.89-1.18) 0.13 0.72    
K (mmol/L) 0.67 (0.44-1.04) 3.14 0.08    
Na (mmol/L) 1.00 (0.94-1.07) 0.01 0.95    
Urea (mmol/L) 1.05 (1.02-1.09) 8.17 0.004    
Thyroid-Stimulating Hormone  (mU/L) 0.97 (0.87-1.08) 0.27 0.60    
Left Atrial Diameter (cm) 2.09 (1.52-2.89) 20.31 <0.001 1.71 (1.20-2.42) 
- 
8.99 
- 
0.003 
- 
 
 
 
 
 
 
 
 
Supplementary table 5. Multivariable analysis for the incidence of atrial fibrillation (AF) in the overall population with heart failure, consistent 
with the 2016 European Society of Cardiology (ESC) guidelines. Two models were constructed, one including and one excluding (table above) 
left atrial diameter. Models included age, sex, systolic blood pressure, diastolic blood pressure, ischemic heart disease, history of paroxysmal 
atrial fibrillation, LogNT-proBNP, albumin, bilirubin, haemoglobin, urea, diagnostic category (HFrEF vs HFpEF).  When added to the model, 
left atrial diameter independently predicted incident AF (HR (95% CI): 1.61 (1.33-1.95) per cm increase, 2 24, P<0.001), competing with 
bilirubin. Only variables independently associated with incident AF are shown. 
 
Variable Multivariable analysis 
 HR (95% CI) 2 p-value 
Age (1 year increase) 1.03 (1.01-1.04) 15 <0.001 
Male sex (vs female) 2.06 (1.51-2.78) 22 <0.001 
Paroxysmal Atrial Fibrillation (yes vs not) 2.68 (1.93-3.71) 35 <0.001 
LogNT-proBNP (ng/L) 2.05 (1.55-2.70) 26 <0.001 
Bilirubin (µmol/L) 1.02 (1.00-1.04) 4 0.047 
